Payment overview · 2025
General Payments
$43.25
1 reported records · 1 companies
Healthcare provider profile · identity verified
Behfar Dianati, M.D.
Allopathic & Osteopathic Physicians|Hospitalist · BELLEVILLE, IL · NPI 1558580852
Verified facts
What the public records show
CMS Open Payments records show Behfar Dianati, M.D. received $43.25 in general payments during 2025 across 1 reported records.
AstraZeneca Pharmaceuticals LP accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $43.25 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $43.25 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ENHERTU Normalized: enhertu |
Biological | AstraZeneca Pharmaceuticals LP | $43.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 810 | 132 |
| Eliquis | Apixaban | 398 | 55 |
| Potassium Chloride | Potassium Chloride | 394 | 66 |
| Furosemide | Furosemide | 374 | 84 |
| Gabapentin | Gabapentin | 319 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 304 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 271 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 269 | 72 |
| Donepezil Hcl | Donepezil Hcl | 262 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 252 | 44 |
| Lisinopril | Lisinopril | 249 | 46 |
| Carvedilol | Carvedilol | 225 | 39 |
| Sertraline Hcl | Sertraline Hcl | 206 | 35 |
| Trazodone Hcl | Trazodone Hcl | 205 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 200 | 41 |
| Mirtazapine | Mirtazapine | 185 | 40 |
| Spironolactone | Spironolactone | 182 | 66 |
| Jardiance | Empagliflozin | 168 | 50 |
| Memantine Hcl | Memantine Hcl | 159 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 156 | 40 |
| Metformin Hcl | Metformin Hcl | 144 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 138 | 42 |
| Montelukast Sodium | Montelukast Sodium | 133 | 16 |
| Losartan Potassium | Losartan Potassium | 115 | 37 |
| Buspirone Hcl | Buspirone Hcl | 113 | 22 |
| Omeprazole | Omeprazole | 111 | 37 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 111 | 12 |
| Levetiracetam | Levetiracetam | 106 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 96 | 49 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 91 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 91 | 13 |
| Prednisone | Prednisone | 87 | 63 |
| Hydralazine Hcl | Hydralazine Hcl | 86 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 86 | 23 |
| Myrbetriq | Mirabegron | 83 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 30 |
| Baclofen | Baclofen | 79 | 16 |
| Entresto | Sacubitril/Valsartan | 76 | 18 |
| Xarelto | Rivaroxaban | 74 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | suppressed |
| Januvia | Sitagliptin Phosphate | 69 | suppressed |
| Meloxicam | Meloxicam | 69 | 13 |
| Finasteride | Finasteride | 67 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 56 | 27 |
| Acetylcysteine | Acetylcysteine | 54 | suppressed |
| Allopurinol | Allopurinol | 52 | 13 |
| Aripiprazole | Aripiprazole | 51 | suppressed |
| Metolazone | Metolazone | 51 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 41 |
| Midodrine Hcl | Midodrine Hcl | 50 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 49 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 48 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 15 |
| Divalproex Sodium | Divalproex Sodium | 47 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 44 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 18 |
| Fenofibrate | Fenofibrate,micronized | 41 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 40 | 14 |
| Cefdinir | Cefdinir | 40 | 33 |
| Trulicity | Dulaglutide | 40 | 14 |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Risperidone | Risperidone | 39 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 37 | suppressed |
| Movantik | Naloxegol Oxalate | 37 | 11 |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Famotidine | Famotidine | 33 | 16 |
| Folic Acid | Folic Acid | 32 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 32 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 25 |
| Simvastatin | Simvastatin | 31 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 30 | 12 |
| Nystatin | Nystatin | 30 | 20 |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 19 |
| Protonix | Pantoprazole Sodium | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 25 | suppressed |
| Multaq | Dronedarone Hcl | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | 14 |
| Divalproex Sodium Er | Divalproex Sodium | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Lubiprostone | Lubiprostone | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 14 |
| Alprazolam | Alprazolam | 22 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 11 |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 22 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 13 |
| Amoxicillin | Amoxicillin | 20 | 15 |
| Azithromycin | Azithromycin | 20 | 19 |
| Fingolimod | Fingolimod Hcl | 20 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 20 | 16 |
| Mirabegron Er | Mirabegron | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | 12 |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Repaglinide | Repaglinide | 18 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 18 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 18 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 15 |
| Tramadol Hcl | Tramadol Hcl | 17 | 14 |
| Bethanechol Chloride | Bethanechol Chloride | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 16 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 16 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 16 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 12 |
| Pregabalin | Pregabalin | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Gvoke Pfs 1-Pack Syringe | Glucagon | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Gvoke Hypopen 1-Pack | Glucagon | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $43.25 · 1 records | AstraZeneca Pharmaceuticals LP | ENHERTU | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error